Iovance Biotherapeutics, Inc. Email Format
Biotechnology ResearchCalifornia, United States501-1000 Employees
Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing tumor infiltrating lymphocyte (TIL) therapies for cancer patients. It aims to harness the immune system to recognize and destroy cancer cells in each individual, pursuing a per-patient treatment strategy. The TIL platform has produced clinical data suggesting activity across several solid tumor types, and the company continues to advance cell-therapy innovations, including gene-edited approaches. The firm is headquartered in the San Francisco Bay Area and operates the Iovance Cell Therapy Center manufacturing facility in Philadelphia, with a research site in Tampa, Florida. As it expands its commercial launch and research efforts, it is building internal manufacturing capabilities to support scale and execution. In 2025, the company appointed Corleen Roche as Chief Financial Officer, with the appointment effective in August 2025.